marginally significantp=0.05
Likewise, patients with KRAS exon 2 mutations in their primary tumors presented higher probability for relapse compared to patients with KRAS exon 2 wild type tumors, but the difference was marginally significant (HR, 1.757; 95% CI, 1.000 to 3.090; p=0.05).